|
Market Closed -
NSE India S.E.
11:05:07 26/10/2026 GMT
|
5-day change | 1st Jan Change | ||
| 328.80 INR | +1.64% |
|
-5.84% | -16.53% |
| 08:23am | Biocon Signs License Agreement to Commercialize Stelara Biosimilar in Nine Markets | MT |
| 10-15 | Biocon Chair: AI in Clinical Trials Is the Holy Grail | MT |
| Market Cap | 535B 5.64B 5.04B 4.65B 4.22B 7.89B 8.02B 55.99B 22.17B 281B 21.17B 20.72B 884B | P/E 2027 * |
49x | P/E 2028 * | 28.8x |
|---|---|---|---|---|---|
| Enterprise Value | 638B 6.72B 6B 5.55B 5.03B 9.4B 9.56B 66.73B 26.42B 334B 25.23B 24.69B 1,054B | EV / Sales 2027 * |
3.29x | EV / Sales 2028 * | 2.81x |
| Free-Float |
51.78% | Yield 2027 * |
0.17% | Yield 2028 * | 0.25% |
| Markets | Quality | ||
|---|---|---|---|
NSE India S.E.
| BIOCON | Delayed | |
Bombay S.E.
| BIOCON | Delayed |
Last Transcript: Biocon Limited
| 1 day | +1.64% | ||
| 1 week | -5.84% | ||
| Current month | -11.21% | ||
| 1 month | -13.96% | ||
| 3 months | -24.18% | ||
| 6 months | -6.02% | ||
| Current year | -16.53% |
| 1 week | 318.4 |  | 344 |
| 1 month | 318.4 | | 381.2 |
| Current year | 318.4 | | 447.15 |
| 1 year | 318.4 | | 447.15 |
| 3 years | 217.5 | | 447.15 |
| 5 years | 191.55 | | 447.15 |
| 10 years | 134.07 | | 487.75 |
| Manager | Title | Age | Since |
|---|---|---|---|
Saurabh Paliwal
IRC | Investor Relations Contact | - | - |
Shreehas Tambe
CEO | Chief Executive Officer | - | 31/03/2026 |
Kedar Upadhye
DFI | Director of Finance/CFO | 48 | 31/03/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 64 | 23/04/2014 | |
| Director/Board Member | 71 | 31/12/1999 | |
| Chairman | 73 | 28/11/1978 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.64% | -5.84% | -8.54% | +46.52% | 5.55B | |
| +0.88% | +1.18% | +40.64% | +74.91% | 64.69B | |
| -0.15% | +6.99% | +9.88% | +77.49% | 54.78B | |
| +0.46% | +3.46% | +9.64% | +100.82% | 53.49B | |
| -0.33% | +4.84% | +28.20% | +51.15% | 45.98B | |
| -0.90% | +1.16% | +18.72% | +125.79% | 42.94B | |
| -0.98% | +1.61% | +219.16% | +829.58% | 40.08B | |
| -2.26% | -2.06% | +15.38% | +45.14% | 33.52B | |
| +0.22% | -4.77% | +26.59% | +0.55% | 23.97B | |
| +12.10% | +16.60% | +58.50% | +46.15% | 23.67B | |
| Average | +1.08% | +1.26% | +41.82% | +139.81% | 38.87B | |
| Weighted average by Cap. | +0.54% | +2.45% | +43.90% | +150.16% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 194B 2.04B 1.82B 1.69B 1.53B 2.86B 2.91B 20.29B 8.03B 102B 7.67B 7.51B 320B | 223B 2.35B 2.1B 1.94B 1.75B 3.28B 3.34B 23.29B 9.22B 117B 8.8B 8.62B 368B |
| Net income | 10.97B 116M 103M 95.32M 86.38M 162M 164M 1.15B 454M 5.75B 434M 424M 18.12B | 17.97B 189M 169M 156M 141M 265M 269M 1.88B 744M 9.41B 710M 695M 29.68B |
| Net Debt | 103B 1.08B 966M 892M 809M 1.51B 1.54B 10.74B 4.25B 53.81B 4.06B 3.97B 170B | 90.59B 954M 852M 787M 713M 1.33B 1.36B 9.47B 3.75B 47.46B 3.58B 3.51B 150B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/10/26 | ₹328.80 | +1.64% | 3,058,458 |
| 23/10/26 | ₹323.50 | -2.06% | 3,471,319 |
| 22/10/26 | ₹330.30 | -1.40% | 2,135,930 |
| 21/10/26 | ₹335.00 | -1.47% | 2,452,266 |
| 19/10/26 | ₹340.00 | -2.63% | 3,222,416 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- BIOCON Stock
Select your edition
All financial news and data tailored to specific country editions
